Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens
Masaru Oba
Oncology letters, 2011
View PDFchevron_right
Single-Agent Irinotecan as Second-Line Treatment for Advanced Gastric Cancer
Mutlu Demiray
Tumori Journal, 2003
View PDFchevron_right
Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice
Manabu Muto
Gastric Cancer
View PDFchevron_right
Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study
Hiroshi Mihara
Gastroenterology research and practice, 2012
View PDFchevron_right
Weekly Irinotecan in Patients with Metastatic Gastric Cancer Failing Cisplatin-based Chemotherapy
Jong Chun
View PDFchevron_right
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study
Vahur Valvere
Annals of Oncology, 2004
View PDFchevron_right
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
Atsuo Takashima
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016
View PDFchevron_right
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes
Dong Gyu Shin
Anti Cancer Drugs, 2005
View PDFchevron_right
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma
Jason Lee
Annals of Oncology, 2006
View PDFchevron_right
Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study
Young Do
Journal of Korean medical science, 2005
View PDFchevron_right
Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens
Masaru Oba
Oncology letters, 2011
View PDFchevron_right
A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer
Dong Shin
Cancer research and treatment : official journal of Korean Cancer Association, 2006
View PDFchevron_right
Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey
Fatih Teker
Asian Pacific journal of cancer prevention : APJCP, 2014
View PDFchevron_right
Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen
Sercan Aksoy
Medical Oncology, 2014
View PDFchevron_right
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
E. Goker
Annals of Oncology, 2008
View PDFchevron_right
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial
Michel Ducreux
British journal of cancer, 2003
View PDFchevron_right
Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer
Kenji Shimada
Cancer Chemotherapy and Pharmacology, 2001
View PDFchevron_right
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
Dimitri Flieger
British Journal of Cancer, 2005
View PDFchevron_right
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Axel Hinke
European Journal of Cancer, 2011
View PDFchevron_right
Phase II Study of Irinotecan plus Leucovorin and Bolus 5-Fluorouracil as First- or Second-Line Chemotherapy in Patients with Advanced Gastric or Esophageal-Gastric Junction Adenocarcinoma
G. Iconomou
Journal of Chemotherapy, 2007
View PDFchevron_right
Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)
Masahiro Takeuchi, Toshikazu Moriwaki
European Journal of Cancer, 2014
View PDFchevron_right
A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer
Gianluca Tomasello
Tumori
View PDFchevron_right
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial
Junichi Sakamoto
European Journal of Cancer, 2015
View PDFchevron_right
Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)
David Cella
Anti-Cancer Drugs, 2011
View PDFchevron_right
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens
Erkan Arpaci
Journal of Chemotherapy, 2012
View PDFchevron_right
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum
Hiroshi Mihara
Anticancer research, 2013
View PDFchevron_right
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
Isabella Sperduti
British journal of cancer, 2007
View PDFchevron_right
A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophageal and Gastric Adenocarcinoma
Craig Earle
Digestive Diseases and Sciences, 2005
View PDFchevron_right